Membranous Nephropathy Trial of Rituximab

Study Overview

The goal of the MENTOR study is to demonstrate via a randomized trial that rituximab is non-inferior to cyclosporine (CSA) in inducing long-term remission of proteinuria in patients with idiopathic membranous nephropathy (iMN). The study involves being randomly assigned to receive either cyclosporine or rituximab for a designated length of time under close physician supervision. The goal is to achieve either partial or complete remission of proteinuria. You will continue to be followed for 2 years after beginning study medication.

Eligibility Criteria

You might be eligible to participate in this study if you:
(1) Are age 18 to 80 years
(2) Have had a kidney biopsy confirming idiopathic membranous nephropathy
(3) Have proteinuria > 5g/24hr
(4) Have an estimated GFR > 40 ml/min/1.73m2
(5) Are willing to have additional lab tests completed to confirm eligibility

You cannot participate in this study if you:
(1) Have Type 1 or 2 diabetes mellitus
(2) Have a history of resistance to Rituximab, alkating agents (such as Cytoxan), Cyclosporine or other calcineurin inhibitors (such as tacrolimus)
(3) Have a secondary cause of membranous nephropathy

How to Get Involved

For more information, or to participate, please contact:

Hailey Desmond, MS, CCRP
Phone: (734) 232-4851